Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,894 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,867 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06955156 | Trilaciclib Combined With Anti-PD-1 Antibody and Chemotherapy in the Treatment of Locally Advanced TNBC | unknown | Phase 2 | 50 | QIAO LIOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT06470672 | Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer | unknown | Phase 2 | 32 | Fudan UniversityOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT04551495 |
| Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE)(ROSALINE) |
| unknown |
| Phase 2 |
| 65 |
| Jules Bordet InstituteOTHER |
| 2 |
| Dec 4, 2024 |
| clinicaltrials |
| NCT06678230 | Clinical Trial of Eribulin in Combination with Anrotinib for HER-2 Negative Locally Advanced or Metastatic Breast Cancer | unknown | Phase 2 | 40 | The First Hospital of Jilin UniversityOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT04913337 | Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | unknown | Phase 1 / Phase 2 | 179 | NGM Biopharmaceuticals, IncINDUSTRY | 3 | Oct 2, 2024 | clinicaltrials |
| NCT06598046 | A Single-arm, Prospective Phase Ⅱ Clinical Study of Utidelone Combined with Capecitabine in the Treatment of Active Brain Metastasis of TNBC | unknown | Phase 2 | 48 | Henan Cancer HospitalOTHER_GOV | 1 | Sep 19, 2024 | clinicaltrials |
| NCT00080756 | Deslorelin Combined With Low-Dose Add-Back Estradiol and Testosterone in Preventing Breast Cancer in Premenopausal Women Who Are at High Risk for This Disease | unknown | Phase 2 | 11 | City of Hope Medical CenterOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT05830097 | A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 260 | Coherent Biopharma (Hefei) Co., Ltd.INDUSTRY | 2 | Aug 26, 2024 | clinicaltrials |
| NCT06471673 | A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer | unknown | Phase 1 / Phase 2 | 18 | BriaCell Therapeutics CorporationINDUSTRY | 1 | Aug 26, 2024 | clinicaltrials |
| NCT06224387 | CTS2190 Phase I /II Clinical Study in Patients | unknown | Phase 1 / Phase 2 | 224 | CytosinLab Therapeutics Co., Ltd.INDUSTRY | 1 | Aug 23, 2024 | clinicaltrials |
| NCT06561022 | Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular Subtyping(abemaSNF1/3) | unknown | Phase 2 | 260 | Fudan UniversityOTHER | 1 | Aug 19, 2024 | clinicaltrials |
| NCT06006390 | CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 60 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06539559 | Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast Cancer | unknown | Phase 2 | 60 | Wang JiayuOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT04303988 | A Phase II Study of Triple-negative Breast Cancer Brain Metastases. | unknown | Phase 2 | 35 | Fudan UniversityOTHER | 1 | Jul 18, 2024 | clinicaltrials |
| NCT06355037 | Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer | unknown | Phase 2 | 10 | Fudan UniversityOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT06311695 | Contrast-Enhanced Spectral Mammography (CESM)(CESM) | unknown | Phase 2 | 263 | European Institute of OncologyOTHER | 1 | Jun 24, 2024 | clinicaltrials |
| NCT04215003 | A Clinical Trial of Breast Cancer Neo-adjuvant Therapy Based on Molecular Pathway in FUSCC | unknown | Phase 1 / Phase 2 | 20 | Fudan UniversityOTHER | 1 | Jun 6, 2024 | clinicaltrials |
| NCT02993198 | A Prospective Study of Breast Cancer Patients With Abnormal Strain Imaging | unknown | Phase 2 | 134 | Northwestern UniversityOTHER | 1 | Jun 3, 2024 | clinicaltrials |
| NCT04418154 | Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients(NeoTENNIS) | unknown | Phase 2 | 70 | Fudan UniversityOTHER | 1 | May 21, 2024 | clinicaltrials |
| NCT05955105 | A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 200 | Innolake BiopharmINDUSTRY | 1 | May 21, 2024 | clinicaltrials |
| NCT06411457 | SHR-A1811 in Combination With Adebrelimab for the Treatment of HER2 Low-expressing Metastatic Breast Cancer | unknown | Phase 2 | 20 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 17, 2024 | clinicaltrials |
| NCT05396118 | Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients | unknown | Phase 2 | 15 | Rigshospitalet, DenmarkOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT05695313 | Randomized Study Versus Placebo for the Prevention of Neurotoxicity Induced by Weekly PACLITAXEL(NEUROTAX) | unknown | Phase 2 | 60 | Centre Georges Francois LeclercOTHER | 1 | Apr 22, 2024 | clinicaltrials |
| NCT05925257 | Digital Health Intervention to Improve Health Care and Outcomes for Breast Cancer Patients | unknown | Phase 2 | 410 | Coordinación de Investigación en Salud, MexicoOTHER_GOV | 1 | Apr 17, 2024 | clinicaltrials |
| NCT05659056 | Neoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast Cancer | unknown | Phase 2 | 65 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT06125834 | Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP Therapy | unknown | Phase 2 | 36 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT05145907 | Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors | unknown | Phase 2 | 133 | TJ Biopharma Co., Ltd.INDUSTRY | 1 | Apr 15, 2024 | clinicaltrials |
| NCT03639948 | Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer(NeoPACT) | unknown | Phase 2 | 120 | University of Kansas Medical CenterOTHER | 1 | Apr 11, 2024 | clinicaltrials |
| NCT04469127 | A Phase I/II Multicenter, Open-Label Study of Lu-177-DOTAGA-IAC, for the Treatment of Angiogenic Breast Cancer Patients.(Heroine01) | unknown | Phase 1 / Phase 2 | 100 | Advanced Imaging Projects, LLCINDUSTRY | 2 | Apr 10, 2024 | clinicaltrials |
| NCT06341842 | Potential Protective Role of SGLT-2 Inhibitors for Chemotherapy-induced Cardiotoxicity(PROTECT) | unknown | Phase 2 | 316 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT06328387 | HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer | unknown | Phase 1 / Phase 2 | 120 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT06308939 | Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial | unknown | Phase 2 | 81 | Zhejiang Cancer HospitalOTHER | 1 | Mar 13, 2024 | clinicaltrials |
| NCT04739670 | Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer(BELLA) | unknown | Phase 2 | 31 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Mar 1, 2024 | clinicaltrials |
| NCT05033925 | Ficus Septica Leaves Fraction as a Complementary Therapy for Stadium IV Breast Cancer Patients | unknown | Phase 1 / Phase 2 | 324 | Gadjah Mada UniversityOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT05574881 | Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer | unknown | Phase 1 / Phase 2 | 72 | Fudan UniversityOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT03474822 | Plasmodium Immunotherapy for Breast and Liver Cancers | unknown | Phase 1 / Phase 2 | 60 | CAS Lamvac Biotech Co., Ltd.INDUSTRY | 1 | Feb 20, 2024 | clinicaltrials |
| NCT03500380 | A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases | unknown | Phase 2 / Phase 3 | 301 | RemeGen Co., Ltd.INDUSTRY | 1 | Feb 20, 2024 | clinicaltrials |
| NCT03924466 | Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients(VUBAR) | unknown | Phase 2 | 55 | Universitair Ziekenhuis BrusselOTHER | 1 | Feb 16, 2024 | clinicaltrials |
| NCT03818685 | Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease(BreastImmune03) | unknown | Phase 2 | 95 | Centre Leon BerardOTHER | 1 | Feb 12, 2024 | clinicaltrials |
| NCT05880394 | Study of Dotatate Imaging in Breast Cancer | unknown | Phase 2 | 30 | Hoag Memorial Hospital PresbyterianOTHER | 1 | Feb 12, 2024 | clinicaltrials |
| NCT05205200 | Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02 | unknown | Phase 2 | 338 | Fudan UniversityOTHER | 1 | Feb 8, 2024 | clinicaltrials |
| NCT05266937 | Atezolizumab Plus CArboplatin Plus Nab-paclitaxel | unknown | Phase 2 | 49 | Consorzio OncotechOTHER | 1 | Feb 1, 2024 | clinicaltrials |
| NCT04914390 | A Phase Ⅱ Study of Anlotinib Combined With Tislelizumab and AT in the Neoadjuvant Treatment of Triple-negative Breast Cancer(NeoATCT) | unknown | Phase 2 | 32 | Sichuan Provincial People's HospitalOTHER | 1 | Jan 22, 2024 | clinicaltrials |
| NCT05464173 | Chidamide in Combination With Abemaciclib and Endocrinotherapy(Doctor's Choice) in Breast Cancer Patients Previously Treated With Palbociclib(CINDERELLA) | unknown | Phase 1 / Phase 2 | 44 | Biyun Wang, MDOTHER | 1 | Jan 22, 2024 | clinicaltrials |
| NCT06210438 | SHR-A1921 Combined With Bevacizumab in Triple-negative Breast Cancer With Brain Metastases | unknown | Phase 2 | 24 | Fudan UniversityOTHER | 1 | Jan 18, 2024 | clinicaltrials |
| NCT05629429 | Olaparib Maintenance Therapy in Metastatic Breast Cancer | unknown | Phase 2 | 300 | National Taiwan University HospitalOTHER | 1 | Jan 17, 2024 | clinicaltrials |
| NCT03812393 | Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast(FACT-2) | unknown | Phase 2 | 27 | West Cancer CenterOTHER | 1 | Dec 18, 2023 | clinicaltrials |
| NCT04197687 | TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery | unknown | Phase 2 | 480 | Academic and Community Cancer Research UnitedOTHER | 1 | Dec 18, 2023 | clinicaltrials |
| NCT05523609 | Vitamin D and Calcium Supplementation in Breast Cancer | unknown | Phase 2 / Phase 3 | 40 | Tanta UniversityOTHER | 1 | Dec 1, 2023 | clinicaltrials |
Data updated 23 days agoSource updated May 2, 2025source: clinicaltrials